The Cardiorenal Connection: Highlighting Cardiovascular Risk in Chronic Kidney Disease

Today’s prevalence of pharmacotherapies for metabolic disease brings focus to the intricate connections between cardiometabolic risk and conditions, particularly in primary care settings. To this point, and  with approximately 50% of CKD patients experiencing cardiovascular complications, an understanding of these connections – with early screening and intervention practices – is crucial for optimal patient outcomes.¹

Here, you’ll receive essential information on implementation of today’s guideline-based recommendations for early detection, risk stratification and timely referral for patients.

Speakers:

Brian Caveney, MD
EVP & President, Research 
Chief Medical and Scientific Officer, Labcorp

Jennifer Ennis, MD FACP
Practicing Nephrologist and Medical Director
Clinical and Digital Solutions, Labcorp